SVSylvia MC Vijgen

Sylvia MC Vijgen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sylvia MC Vijgen has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial)

    by Smc Vijgen, Cm Koopmans, Bc Opmeer, H Groen, D Bijlenga, Jg Aarnoudse, Dj Bekedam, Pp van Den Berg, K de Boer, Jm Burggraaff, et al.

    Please cite this paper as:Vijgen S, Koopmans C, Opmeer B, Groen H, Bijlenga D, Aarnoudse J, Bekedam D, van den Berg P, de Boer K, Burggraaff J, Bloemenkamp K, Drogtrop A, Franx A, de Groot C, Huisjes A, Kwee A, van Loon A, Lub A, Papatsonis D, van der Post J, Roumen F, Scheepers H, Stigter R, Willekes C, Mol B, Van Pampus M for the HYPITAT study group. An economic analysis of induction of labour and expectant monitoring in women with gestational hypertension or pre‐eclampsia at term (HYPITAT trial). BJOG 2010;117:1577–1585.Objective To assess the economic consequences of labour induction compared with expectant monitoring in women with gestational hypertension or pre‐eclampsia at term.Design An economic analysis alongside the Hypertension and Pre‐eclampsia Intervention Trial At Term (HYPITAT).Setting Obstetric departments of six university and 32 teaching and district hospitals in the Netherlands.Population Women diagnosed with gestational hypertension or pre‐eclampsia between 36+0and 41+0 weeks of gestation, randomly allocated to either induction of labour or expectant monitoring.Methods A trial‐based cost‐effectiveness analysis was performed from a societal perspective during a 1‐year time horizon.Main outcome measures One‐year costs were estimated and health outcomes were expressed as the prevalence of poor maternal outcome defined as either maternal complications or progression to severe disease.Results The average costs of induction of labour (n = 377) were €7077 versus €7908 for expectant monitoring (n = 379), with an average difference of −€831 (95% CI −€1561 to −€144). This 11% difference predominantly originated from the antepartum period: per woman costs were €1259 for induction versus €2700 for expectant monitoring. During delivery, more costs were generated following induction (€2190) compared with expectant monitoring (€1210). No substantial differences were found in the postpartum, follow‐up and for non‐medical costs.Conclusion In women with gestational hypertension or mild pre‐eclampsia at term, induction of labour is less costly than expectant monitoring because of differences in resource use in the antepartum period. As the trial already demonstrated that induction of labour results in less progression to severe disease without resulting in a higher caesarean section rate, both clinical and economic consequences are in favour of induction of labour in these women.Trial registration The trial has been registered in the clinical trial register as ISRCTN08132825.


  • Open Access

    Assessment of perinatal outcome after sustained tocolysis in early labour (APOSTEL-II trial)

    by Carolien Roos, Liesbeth Hcj Scheepers, Kitty Wm Bloemenkamp, Annemiek Bolte, Jerome Cornette, Jan B Derks, Hans Jj Duvekot, Jim van Eyck, Joke H Kok, Anneke Kwee, et al.

    Preterm labour is the main cause of perinatal morbidity and mortality in the Western world. At present, there is evidence that tocolysis for 48 hours is useful in women with threatened preterm labour at least before 32 weeks. This allows transfer of the patient to a perinatal centre, and maximizes the effect of corticosteroids for improved neonatal survival. It is questionable whether treatment with tocolytics should be maintained after 48 hours.